← Browse by Condition
Medical Condition
alk gene mutation
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT06378892 Phase 2
Recruiting
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Enrollment
45 pts
Location
Italy
Sponsor
Centro di Riferimento Oncologi...
NCT04322890 Phase 2
Recruiting
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Enrollment
6,000 pts
Location
China
Sponsor
Hunan Province Tumor Hospital